Clinical trials: Tolerability
Healthy Volunteers
A SAD, MAD and Food Effect Study to Evaluate the Safety, Tolerability, PK, and PD of AJA001 in Healthy Subjects
This is a Phase 1, double-blind, randomized, placebo- controlled, SAD and MAD study to assess safety, tolerability, PK, and PD of AJA001 in fasted healthy participants.
- Trial name
- NCT06019065
- Testing
- AJA001
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AJNA Australia Pty Ltd
Arthritis, Rheumatoid
Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments.
- Trial name
- NCT02480946
- Testing
- MBS2320, Methotrexate
- Where
- 3 sites in United Kingdom
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Modern Biosciences Ltd
Influenza
Phase II Study of Pandemic Influenza Vaccine
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next influenza pandemic.
- Trial name
- NCT00320346
- Testing
- Pandemic Influenza Vaccine
- Where
- 3 sites in Australia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Seqirus
Smallpox, Monkeypox
Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years
The aim of the clinical study is to study the safety and tolerability of the live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus, in intracutaneous administration.
- Conditions
- Smallpox, Monkeypox, Cowpox, Vaccinia Virus Infection
- Trial name
- NCT05762523
- Testing
- VAC∆6 vaccine - оnce at a dose of 10⁶ PFU, VAC∆6 vaccine - once at a dose of 10⁷ PFU, VAC∆6 vaccine - twice at a dose of 10⁶ PFU
- Where
- Russia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
Paramyxoviridae Infections, Virus Diseases
Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children
Human parainfluenza viruses (HPIVs) are a major health concern in infants and young children under 5 years of age, causing serious respiratory tract disease.
- Trial name
- NCT01021397
- Testing
- rHPIV3cp45
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy, Colitis, Ulcerative
A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis
The purpose of this study is to evaluate safety and tolerability of JNJ 66525433 compared with placebo after administration of: 1) single ascending oral doses of JNJ 66525433 administered to healthy participants (Part 1), 2)…
- Trial name
- NCT04457960
- Testing
- JNJ-66525433
- Where
- Germany
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers
Dose escalation study to assess the safety and tolerability of TB-402, a monoclonal antibody directed against FVIII, versus placebo in healthy male volunteers.
- Trial name
- NCT00612196
- Testing
- TB-402
- Where
- Denmark
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- ThromboGenics
Psoriasis, Healthy
A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)
The purpose of this trial is to learn about a trial medicine called MK-8644. This trial is the first time researchers will give MK-8644 to people.
- Trial name
- NCT07850310
- Testing
- MK-8644
- Where
- Australia
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy Subjects
The purpose of the study is to evaluate the safety and tolerability of multiple ascending oral doses of GLPG0634 given to healthy subjects for 10 days compared to placebo.
- Trial name
- NCT01419990
- Testing
- GLPG0634
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Tooth Extraction
Safety, Tolerability and Efficacy Study of TT-173 in Healthy Volunteers After Tooth Extraction
The purpose of this study is to evaluate the safety, tolerability and efficacy of TT-173 in healthy volunteers after tooth extraction.
- Trial name
- NCT01595360
- Testing
- TT-173
- Where
- Spain
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Thrombotargets Europe S.L
RSV Infection
A Study of EDP-938 in Healthy Subjects
This randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-938 in healthy adult subjects
- Trial name
- NCT03384823
- Testing
- EDP-938
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Healthy
A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate
This study will assess the safety, tolerability and blood concentrations of lasmiditan and topiramate together compared to lasmiditan and topiramate separately. Information about any side effects that may occur will be collected.
- Trial name
- NCT03308669
- Testing
- Lasmiditan, Topiramate
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants
The purpose of this study is to assess safety and tolerability of day-time and night-time dosing of JNJ-55375515 in healthy male participants.
- Trial name
- NCT03405441
- Testing
- JNJ-55375515 Dose Level 1, JNJ-55375515 Dose Level 2, JNJ-55375515 Dose Level 3
- Where
- Netherlands
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
The purpose of this study is to assess the safety and tolerability of AMG 139 following multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and in subjects with mild to severe Crohn's disease…
- Trial name
- NCT01258205
- Testing
- AMG 139
- Where
- 7 sites in United States, Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
HIV, AIDS
TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.
The purpose of this study is to investigate the pharmacokinetics (how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body) after a single dose and after repeated administration of…
- Conditions
- HIV, AIDS, Hepatic Impairment
- Trial name
- NCT00736905
- Testing
- TMC278
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Healthy
Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy Volunteers
This study is a phase 1 study of PF-06651600. PF-06651600 is being developed for treatment of inflammatory bowel disease. The goal of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of…
- Trial name
- NCT03232905
- Testing
- PF-06651600
- Where
- Belgium
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Celiac Disease, Healthy
A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
The goal of this clinical trial is to learn about the safety of a single dose of HB-2121 in adults. It will also look at how the body processes the drug.
- Trial name
- NCT07063823
- Testing
- HB-2121
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Nielsen Fernandez-Becker
Healthy Adult Subjects
PSTB100 Study in Healthy Adult Subjects
This study is a randomized, double-blind, placebo-controlled, dose-escalation， first-in-human clinical trial in healthy adults, designed to assess the safety, tolerability, and PK characteristics of PSTB100 tablets.
- Trial name
- NCT07702279
- Testing
- PSTB100 tablets
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Prospect Therapeutics (Nanjing) Limited
To Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS Monoclonal Antibodies in HIV-negative Women
A Phase II Trial to Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS in HIV- Negative Women
A double blinded, Randomized, Placebo- controlled phase II trial to assess extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV- negative women
- Trial name
- CAPRISA 012C (NCT07810062)
- Testing
- Broad band monoclonal antibodies named as CAP256V2LS and VRC07- 523LS
- Where
- Zambia
- Volunteers
- 990 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Moderate to Severe Plaque Psoriasis
Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects
This is a first-in-human, phase 1, single-center, randomized, double blinded, placebo-controlled, single dose-escalation study to evaluate the safety, tolerability, PK, of 608 following subcutaneous injection in healthy subjects.
- Trial name
- NCT04367441
- Testing
- 608
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.